115 related articles for article (PubMed ID: 38444679)
21. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
22. Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy.
Frontiers Editorial Office
Front Oncol; 2023; 13():1285219. PubMed ID: 37731635
[TBL] [Abstract][Full Text] [Related]
23. Retraction: Establishment of criteria for molecular differential diagnosis of MPC and IPM.
Frontiers Editorial Office
Front Oncol; 2024; 14():1399853. PubMed ID: 38577339
[TBL] [Abstract][Full Text] [Related]
24. Retraction: Evaluation of the safety of retroperitoneal laparoscopic partial nephrectomy by investigating the perioperative indicators.
Frontiers Editorial Office
Front Oncol; 2024; 14():1383340. PubMed ID: 38440232
[TBL] [Abstract][Full Text] [Related]
25. Retraction: Identification of hub genes and construction of prognostic nomogram for patients with Wilms tumors.
Frontiers Editorial Office
Front Oncol; 2023; 13():1301668. PubMed ID: 37965462
[TBL] [Abstract][Full Text] [Related]
26. Retraction: RBFOX3 Promotes Gastric Cancer Growth and Progression by Activating HTERT Signaling.
Frontiers Editorial Office
Front Oncol; 2021; 11():738970. PubMed ID: 34532292
[TBL] [Abstract][Full Text] [Related]
27. Retraction: AnnexinA5 might suppress the phenotype of human gastric cancer cells via ERK pathway.
Frontiers Editorial Office
Front Oncol; 2023; 13():1294881. PubMed ID: 37841426
[TBL] [Abstract][Full Text] [Related]
28. Retraction: Ppm1b Negatively Regulates 3-Bromopyruvic Acid Induced Necroptosis in Breast Cancer Cells.
Frontiers Editorial Office
Front Oncol; 2021; 11():757083. PubMed ID: 34513719
[TBL] [Abstract][Full Text] [Related]
29. Retraction: CDX2/mir-145-5p/SENP1 Pathways Affect LNCaP Cells Invasion and Migration.
Frontiers Editorial Office
Front Oncol; 2021; 11():744978. PubMed ID: 34490129
[TBL] [Abstract][Full Text] [Related]
30. Retraction: ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer.
Frontiers Editorial Office
Front Oncol; 2021; 11():734761. PubMed ID: 34350126
[TBL] [Abstract][Full Text] [Related]
31. Retraction: New insights into molecular signalling pathways and current advancements in prostate cancer diagnostics and therapeutics.
Frontiers Editorial Office
Front Oncol; 2023; 13():1343833. PubMed ID: 38130994
[TBL] [Abstract][Full Text] [Related]
32. Retraction: MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway.
Frontiers Editorial Office
Front Oncol; 2023; 13():1298871. PubMed ID: 37881488
[TBL] [Abstract][Full Text] [Related]
33. Retraction: Long noncoding RNA SNHG1 activates autophagy and promotes cell invasion in bladder cancer.
Office FE
Front Oncol; 2023; 13():1228367. PubMed ID: 37377910
[TBL] [Abstract][Full Text] [Related]
34. Retraction: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.
Frontiers Editorial Office
Front Oncol; 2021; 11():839904. PubMed ID: 35036357
[TBL] [Abstract][Full Text] [Related]
35. Retraction: Corrigendum: CDX2/mir-145-5p/SENP1 Pathways Affect LNCaP Cells Invasion and Migration.
Frontiers Editorial Office
Front Oncol; 2021; 11():744980. PubMed ID: 34490130
[TBL] [Abstract][Full Text] [Related]
36. Retraction: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.
Frontiers Editorial Office
Front Oncol; 2021; 11():694036. PubMed ID: 34041039
[TBL] [Abstract][Full Text] [Related]
37. The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors.
Lu S; Hong Y; Chen H; Wu L; Sun F; Wang J; Zhu J; Que Y; Zhang L; Zhen Z; Sun X; Huang J; Zhang Y
Front Pharmacol; 2022; 13():711704. PubMed ID: 35431969
[No Abstract] [Full Text] [Related]
38. Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin.
Frontiers Editorial Office
Front Oncol; 2023; 13():1337635. PubMed ID: 38130993
[TBL] [Abstract][Full Text] [Related]
39. Retraction: LncRNA TCF7 promotes epithelial ovarian cancer viability, mobility and stemness via regulating ITGB8.
Frontiers Editorial Office
Front Oncol; 2023; 13():1307324. PubMed ID: 37927471
[TBL] [Abstract][Full Text] [Related]
40. Retraction: OTUB2 facilitates tumorigenesis of gastric cancer through promoting KDM1A-mediated stem cell-like properties.
Frontiers Editorial Office
Front Oncol; 2023; 13():1209867. PubMed ID: 37287909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
